Loading institutional data...
Loading institutional data...
Strong institutional accumulation: ownership increased +3.53% quarter-over-quarter.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $9.52 today, the market must believe free cash flow compounds 2.7%/yr for a decade (off $36M normalized FCF).
The market's 2.7% is more conservative than its 6-yr track record.
2-stage DCF · 0.05B shares · net debt $16M
mean 503.8% · volatility σ 1253% · implied rate exceeded in 3/5 yrs
Central path = implied 2.7%/yr growth; shaded band = ±1σ (1253%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $228.4M 100.0% | $230.5M 100.0% | $235.6M 100.0% | $228.0M 100.0% | $253.2M 100.0% | $225.1M 100.0% | $272.3M 100.0% | $251.0M 100.0% | $27.7M 100.0% | — |
| Cost of Revenue | $58.2M 25.5% | $64.4M 27.9% | $62.7M 26.6% | $55.1M 24.2% | $63.7M 25.2% | $39.4M 17.5% | $36.8M 13.5% | $34.6M 13.8% | $5.6M 20.1% | — |
| Cost of Products | — | — | — | — | — | — | — | — | $5.6M 20.1% | — |
| Research & Development | — | — | — | — | $71.9M 28.4% | $97.7M 43.4% | $132.9M 48.8% | $164.9M 65.7% | $207.8M 750.6% | $222.8M |
| Selling, General & Admin | $70.8M 31.0% | $80.2M 34.8% | $89.9M 38.2% | $90.0M 39.5% | $116.3M 45.9% | $118.5M 52.6% | $141.6M 52.0% | $146.2M 58.2% | $106.7M 385.4% | $53.8M |
| Total Operating Expenses | $191.1M 83.7% | $199.5M 86.6% | $203.0M 86.1% | $204.3M 89.6% | $251.9M 99.5% | $255.5M 113.5% | $311.3M 114.3% | $345.6M 137.7% | $320.1M 1156.1% | $276.6M |
| Operating Income | $37.3M 16.3% | $31.0M 13.4% | $32.6M 13.9% | $23.7M 10.4% | $1.3M 0.5% | -$30.4M -13.5% | -$39.0M -14.3% | -$94.7M -37.7% | -$292.4M -1056.1% | -$276.6M |
| Interest Expense | $6.6M 2.9% | $12.5M 5.4% | $13.3M 5.7% | $11.6M 5.1% | $12.8M 5.1% | $14.0M 6.2% | $15.0M 5.5% | $11.0M 4.4% | $720K 2.6% | — |
| Interest & Investment Income | $4.1M 1.8% | $4.7M 2.0% | $2.6M 1.1% | $813K 0.4% | $160K 0.1% | $489K 0.2% | $2.8M 1.0% | $1.8M 0.7% | $1.3M 4.5% | $958K |
| Other Income (Expense), net | -$1.5M -0.7% | -$6.9M -3.0% | -$10.0M -4.2% | -$23.3M -10.2% | -$30.1M -11.9% | -$29.4M -13.1% | -$36.5M -13.4% | -$18.9M -7.5% | $435K 1.6% | $585K |
| Pretax Income | $35.8M 15.7% | $24.1M 10.5% | $22.7M 9.6% | $457K 0.2% | -$28.8M -11.4% | -$59.8M -26.6% | -$75.5M -27.7% | -$113.6M -45.2% | — | — |
| Income Tax Expense | $4.7M 2.0% | -$6.2M -2.7% | $1.1M 0.5% | $455K 0.2% | $324K 0.1% | $207K 0.1% | $53K 0.0% | $17K 0.0% | $0 0.0% | $0 |
| Net Income | $31.1M 13.6% | $30.3M 13.1% | $21.6M 9.2% | $2K 0.0% | $29.1M 11.5% | -$60.0M -26.7% | -$75.6M -27.8% | -$113.6M -45.3% | -$292.0M -1054.6% | -$276.0M |
| Per Share | ||||||||||
| EPS (Basic) | $0.62 | $0.62 | $0.46 | $0.00 | $-0.72 | $-1.52 | $-75595.00 | — | — | — |
| EPS (Diluted) | $0.61 | $0.62 | $0.45 | $0.00 | $-0.72 | $-1.52 | — | — | — | — |
| Weighted Avg Shares (Basic) | 50.0M | 48.6M | 47.1M | 44.7M | 40.6M | 39.6M | — | — | — | — |
| Weighted Avg Shares (Diluted) | 50.7M | 49.1M | 47.6M | 44.9M | 40.6M | 39.6M | — | — | — | — |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Earnings are backed by cash (FCF ≥ net income) — high quality. Lower/negative accruals = higher quality (Sloan).
Comfortably covers interest; leverage falling year-over-year.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned on $42M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Reinvestment has been productive — operating income grew well per dollar put in. Current ROIC on all capital: 18%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $30M covers the $0 due within a year 29635000.0× over. Scheduled principal only (excludes interest & revolver draws). As of 2022-09-30 (10-Q).
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Coverage is adequate but not comfortable. Effective rate ~14.7% on $45M of debt.
Cash of $30M fully covers short-term debt of $23M.
Mostly short-term debt (balance-sheet current vs non-current split). See the maturity ladder above for the year-by-year repayment schedule.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
EOD close · as of 2026-09-17
No material risks flagged.
Where each multiple sits in its own 14-yr range · 69th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 14-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Returns are margin-driven, not leverage-driven — higher quality.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Profit and sales moved in opposite directions this year.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 13.8 | 13.5 | 17.5 | 25.2 | 24.2 | 26.6 | 27.9 | 25.5 |
| R&D | 65.7 | 48.8 | 43.4 | 28.4 | — | — | — | — |
| SG&A | 58.2 | 52.0 | 52.6 | 45.9 | 39.5 | 38.2 | 34.8 | 31.0 |
| Operating Income | -37.7 | -14.3 | -13.5 | 0.5 | 10.4 | 13.9 | 13.4 | 16.3 |
| Income Tax | 0.0 | 0.0 | 0.1 | 0.1 | 0.2 | 0.5 | -2.7 | 2.0 |
| Net Income | -45.3 | -27.8 | -26.7 | 11.5 | 0.0 | 9.2 | 13.1 | 13.6 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on PBYI: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.20T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.02T | 49.6× | — | 15.7× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $916.2B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $643.4B | 24.2× | — | 6.8× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $464.4B | 111.2× | 33.2× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $362.6B | 19.9× | — | 5.6× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $340.0B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $252.6B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $244.5B | 36.5× | 31.5× | 5.5× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $202.8B | 26.4× | 17.4× | 5.5× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $183.3B | 21.8× | 20.0× | 6.2× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.2B | 27.5× | 19.3× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $156.1B | 20.2× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $147.3B | 41.3× | 30.5× | 6.0× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $135.8B | 48.6× | 37.3× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $130.4B | 33.5× | 28.6× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $129.4B | 18.4× | — | 2.7× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.5B | 24.8× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| LGVN | $117.4B | — | — | 97924.4× | -49.9% | 67.0% | -1894% | -400% | -400% | — | 31 |
| CVS | $116.6B | 66.0× | 11.7× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $108.8B | 33.9× | 18.7× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $103.4B | 23.1× | 16.3× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.7B | 15.2× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.1B | 16.4× | 15.4× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $81.0B | 18.7× | 19.4× | 5.7× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| PBYI | $473M | 15.4× | 13.0× | 2.1× | -0.9% | 74.5% | 13.6% | 23.9% | 17.7% | 1.2× | 151 |
Peers = companies sharing PBYI's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.